Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, vol.30, issue.13, pp.1553-1561, 2012. ,
DOI : 10.1200/JCO.2011.39.9436
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14, PLOS ONE, vol.21, issue.7, 2015. ,
DOI : 10.1371/journal.pone.0123978.t004
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.4, pp.235-242, 2002. ,
DOI : 10.1056/NEJMoa011795
First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.8003, 2011. ,
DOI : 10.1200/jco.2011.29.15_suppl.8003
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial, The Lancet, vol.378, issue.9806, pp.1858-1867, 2011. ,
DOI : 10.1016/S0140-6736(11)61040-4
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.6, pp.525-533, 2013. ,
DOI : 10.1016/S1470-2045(13)70122-0
Prognosis of body mass index and chemotherapy dose capping in acute myeloid leukaemia, Leukemia Research, vol.38, issue.12, pp.1425-1429, 2014. ,
DOI : 10.1016/j.leukres.2014.09.013
Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese, Journal of Clinical Oncology, vol.25, issue.30, pp.4707-4713, 2007. ,
DOI : 10.1200/JCO.2007.11.2938
Pharmacokinetics of Doxorubicin In Normal Weight and Obese Lymphoma Patients, Blood, vol.116, issue.21, pp.4935-4935, 2010. ,
Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma, Leukemia & Lymphoma, vol.14, issue.9, pp.1649-1657, 2010. ,
DOI : 10.1001/jama.295.7.826
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma, Annals of Oncology, vol.119, issue.14, pp.171-176, 2014. ,
DOI : 10.1182/blood-2011-09-380949
Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients, Leukemia & Lymphoma, vol.33, issue.11, pp.1-9, 2016. ,
DOI : 10.1093/annonc/mdt481
Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity, The American Journal of Cardiology, vol.112, issue.12, pp.1980-1984, 2013. ,
DOI : 10.1016/j.amjcard.2013.08.026
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, British Journal of Haematology, vol.854, issue.5, pp.699-702, 2014. ,
DOI : 10.1007/s00280-010-1487-6